Lung Cancer

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

Patients with NSCLC who received postoperative radiation therapy lived 4 months longer on average than patients who did not receive radiation but who had the same disease site, tumor histology, and treatment criteria, according to a large retrospective study.

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

Molecular profiling has revealed several tumor markers that could be utilized as therapeutic targets for patients with small cell lung cancer (SCLC) or lung neuroendocrine tumors (NETs).

A new study suggests a knowledge gap in Primary Care Providers' familiarity with screening guidelines could also be a barrier to successful implementation.

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

Biopsies were found to be the most costly tool used in lung cancer diagnosis, and may be performed too frequently based on negative test results and adverse events.

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of patients with non-small cell lung cancer (NSCLC) who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.

Suresh S. Ramalingam, MD, discusses results from a phase II trial exploring the potential of veliparib as a treatment for patients with squamous cell NSCLC.

The treatment of patients with non-small cell lung cancer (NSCLC) who harbor an actionable mutation in EGFR or ALK continues evolve, as clinical trials begin exploring next-generation agents and combination strategies.